FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 03/2022”.
The Monitor is a month-to-month printed overview of enterprise capital developments within the European Life Sciences sector.
As of the top of March 2022 we establish the next present VC developments in Europe:
- In 2022, total Life Sciences funding has reached EUR 2,880m so farTop 5 Offers exceed EUR 70m every, largest transaction amounted to EUR 500m in Doctolib (France)
- Bpifrance dominates the Prime 5 Buyers (by deal quantity), adopted by Eurazeo (France) and Normal Atlantic (United States)
- The Biotech sector acquired 42% of the entire funding quantity, no change in comparison with the earlier month
- Oncology dominates as the highest indication of the Biotechnology sector
To entry the complete report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink